Life Sciences MVP: Morrison & Foerster's David Doyle

Explore:  Life Sciences

Morrison & Foerster LLP partner David C. Doyle has successfully fought for generic drug companies’ access to markets years before competitors’ exclusivity runs out, including Sandoz Inc.’s bid to invalidate Teva Pharmaceutical USA Inc.’s patents for its $3 billion a year Copaxone drug, netting him a spot on Law360’s list of Life Sciences MVPs.

Doyle, who leads Morrison’s Abbreviated New Drug Application litigation group from the firm’s San Diego office, says he was drawn to science law because of the added complexity of the inner workings of living systems, in addition to the intricacies of the law.

Originally published in Law360 on December 13, 2013.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Life Sciences

Published In: Intellectual Property Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »